PMS60 The Introduction Of Biosimilar Monoclonal Antibodies Into Developed Markets: What Are Payers Concerned About?  by Sewak, N.P.S. et al.
 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  A229 
 
 
CZP also improved household productivity and increased participation in social 
and daily activities.  
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PMS60  
THE INTRODUCTION OF BIOSIMILAR MONOCLONAL ANTIBODIES INTO 
DEVELOPED MARKETS: WHAT ARE PAYERS CONCERNED ABOUT?  
Sewak NPS, Whitcher C, Neophytou I 
Double Helix Consulting, London, UK  
OBJECTIVES: The introduction of biosimilar monoclonal antibodies into the 
market is thought to be eagerly awaited by payers. This is motivated by the need 
to constrain prescribing costs due to the ever burdening pressure on health care 
budgets. The objectives of this research were to explore payers’ attitudes 
towards the introduction of biosimiliars into the UK National Health Service, and 
to identify the key concerns of payers towards the entry of biosimilars into the 
market. As the UK is widely recognised as a leading health care market the 
outputs from this research can be applied to other developed markets. 
METHODS: A thorough literature review was carried out identifying the current 
regulatory stance and other national guidance on the introduction of biosimilar 
monoclonal antibodies. From this a series of value messages were formulated 
around four themes: the manufacture of biosimilar monoclonal antibodies, 
extrapolation of clinical data, generic substitution and interchangeability and 
pharmacovigilance. These value messages were then tested with national payers 
to identify key priority areas. RESULTS: Payers identified that interchangeability 
and pharmacovigilance were the priority areas which needed to be addressed at 
both a national and local level to manage the entry of biosimilar monoclonal 
antibodies. In particular they identified immunogenicity as a key area of concern 
due to the long acting nature of biosimilar monoclonal antibodies. They also 
recommended a greater emphasis on the use of electronic prescribing systems to 
ensure that the appropriate recording of the originator product or biosimilar is 
documented and can be traced back to an individual patient. This should be 
mandated at a national level supported by local hospital protocols. 
CONCLUSIONS: Payers are aware of the introduction of biosimilar monoclonal 
antibodies into the market. They recognise that a managed entry assisted by the 
regulatory authorities alongside locally agreed guidance will be crucial to a 
successful roll-out  
 
PMS61  
COMPARISON OF CLINICAL CHARACTERISTICS OF PATIENTS WITH 
RHEUMATOID ARTHRITIS (RA) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To assess the clinical characteristics of patients with RA receiving 
their first biologic in 5EU. METHODS: A multi-country multi-center medical 
chart-review study of RA patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >2RA biologic patients/week) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>5) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status. RESULTS: In 1Q2012, 2208 eligible RA patient charts were abstracted; 1562 
(71%) patients were on their first biologic (mean-age:50.7yrs, female:71%). 
Geographic distribution of patients were - UK:19%, Germany:18%, France:22%, 
Italy:23%, Spain:18%. Time-to-1stbiologic from diagnosis (range:31mo (Italy)-52mo 
(France)) and time-on-current biologic (range:17month (Italy)-27month (France)) 
differed within 5EU. The top-3 reasons for biologic treatment initiation were 
consistent across 5EU (‘mechanism of action’, ‘improve signs/symptoms’, 
‘prevent structural damage’), whereas the next 2 reasons differed (UK/Germany: 
‘disease worsened’ & ‘positive personal experience’; France: ‘inhibits disease’ & 
‘mode of administration’; Italy: ‘frequency of administration’ & ‘positive personal 
experience’; Spain: ‘positive personal experience’ & ‘inhibits disease 
progression’). Key lab measures documented were: ESR (range:20.8mm/h 
(France)-29.1mm/h (Italy)) and CRP (range:6.9mg/dl (Spain)-15.0mg/dl (UK)). 
Current disease severity per physician-judgment (mild:moderate:severe) in 5EU 
were: UK-58%:29%:13%, Germany-50%:44%:7%, France-39%:48%:12%, Italy-
47%:49%:4%, Spain-59%:36%:5%. Among patients with available data, current 
HAQ (range: 0.7(Spain)-1.5(Germany)), DAS28 (range:3.0(Spain)-3.8(Germany)), 
100mmVAS (range:23.3(France)-34.8(Italy)) and Total Sharp (range:0.9(France)-
(3.6(Germany)) differed within 5EU. CONCLUSIONS: Among RA patients receiving 
their first biologic, disease severity differed within 5EU, with patients in 
Germany with relatively higher burden. Impact of specific biologic treatments on 
the observed patterns warrants further scrutiny.  
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A MULTI-COUNTRY PHYSICIAN SURVEY ON PATIENT ELIGIBILITY AND USE OF 
BIOLOGICS IN RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS) 
AND PSORIATIC ARTHRITIS (PSA) IN EUROPEAN UNION (EU)  
Narayanan S1, Lu Y2, Hutchings R2, Baskett A2 
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To assess physician assessment of patient eligibility and eventual 
use of biologics in RA, AS and PsA in EU. METHODS: A multi-country physician 
survey was conducted in 5EU (UK, Germany, Spain, France, Italy) in RA, AS and 
PsA. Physicians were screened for experience (3-30yrs) and biologic patient 
volume (>2RA biologic patients/week, >5AS biologic patients/month, >5PsA 
biologic patients/month) and recruited from a large physician-panel to be 
geographically representative in each country. Practice characteristics, patient-
volume, physician perceptions and practice patterns were assessed; physicians’ 
target patient population was grouped into 2 categories, based on physician 
input: Group1 – patients perceived to be eligible for biologics, Group2 – patients 
who ended up receiving biologics within Group1. Summary statistics across 5EU 
are reported. RESULTS: In the first quarter 2012, 434 physicians (rheumatologists: 
97%; internist: 3%) participated in the study. Mean age: 45yrs; female: 35%; 
exclusively hospital-based practice:71%. Geographic distribution of physicians 
was: UK-18%, Germany-19%, Spain-19%, France-22%, Italy-22%. Patient volume 
per physician was: total-1065, RA-207, AS-80, PsA-88. Average frequency of 
patient encounters were: RA-11wks, AS-12wks, PsA-11wks. Physician global 
assessment of patient disease severity were (average across patients): RA mild: 
35%/moderate: 41%/severe: 23%, AS – mild: 37%/moderate: 39%/severe: 24% and 
PsA–mild: 37%/moderate:39%/severe: 24%. Physician assessment of patient 
eligibility and use of biologics were: within RA-mild-patients – Group1: 
18%/Group2: 10%, within RA-moderate-patients–Group1: 45%/Group2: 33%, 
within RA-severe-patients–Group1: 76%/Group2: 66%; within AS-mild-patients–
Group1: 20%/Group2: 11%, within AS-moderate-patients–Group1: 48%/Group2: 
37%, within AS-severe-patients–Group1: 77%/Group2: 69%; within PsA-mild-
patients–Group1: 22%/Group2: 12%, within PsA-moderate-patients–Group1: 
51%/Group2: 37%, within PsA-severe-patients–Group1: 76%/Group2: 66%; Among 
patients who received biologics, Enbrel, Humira and Remicade were the top-3 
prescribed medications across RA/AS/PsA. CONCLUSIONS: Across the markets, 
approximately one-tenth of biologic eligible patients (per physician perception) 
within corresponding disease severity groups did not end up receiving a biologic, 
across RA/AS/PsA, with the discordance slightly more pronounced within 
moderate patients. Reasons behind these patterns and the impact on subsequent 
patient outcomes warrants further scrutiny.  
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VALUE-BASED INSURANCE DESIGN INFORMED BY GOVERNMENT RESEARCH: A 
CASE STUDY OF OSTEOPOROSIS FRACTURES  
Cangelosi MJ, Zhong Y, Winn A, Chambers JD 
Tufts Medical Center, Boston, MA, USA  
OBJECTIVES: To use a mixed-treatment meta-analysis and simulation model to 
estimate fracture reductions and cost savings achievable from switching 
osteoporosis patients to more efficacious treatments in a large health plan. 
METHODS: We populated the Bayesian mixed-treatment meta-analysis using 
studies identified within a recent AHRQ systematic review of anti-osteoporosis 
agents. We considered anti-osteoporosis drugs included in a health plan’s 
pharmacy benefit, i.e., alendronate, ibandronate, raloxifene, risedronate, and 
teriparatide and these drugs’ effect upon the clinical endpoints of vertebral, hip, 
and other fractures. We used the results of the meta-analysis to populate a 
stochastic simulation model to examine a cohort of 13,337 individuals with an 
osteoporosis diagnosis in a large private health plan. We compared the expected 
number of vertebral, hip, and other fractures and cost of care (drug and 
hospitalization costs) between the existing distribution of treatments as 
identified by claims data and a distribution optimized in accordance with the 
mixed-treatment meta-analysis. We obtained drugs costs from claims data and 
hospitalization costs from the literature. RESULTS: Results from the mixed-
treatment meta-analysis suggest that ibandronate and raloxifene are associated 
with worse outcomes than alendronate, risedronate, and teriparatide across the 
considered endpoints. Therefore, our simulation switched patients from 
ibandronate and raloxifene and increased the proportion of patients treated with 
alendronate, risedronate, and teriparatide. Results suggest a substantial 
reduction in clinical events and economic savings (18% reduction of clinical 
events, including a 30% reduction in new hip fractures, a 5% in vertebral 
fractures, and a 9% reduction in other fractures). We estimate total economic 
savings to the health plan of over $750 per covered patient, over $10 million in 
aggregate. CONCLUSIONS: Opportunities to leverage existing research can help 
inform value-based pharmacy benefit design. The optimized allocation of 
treatments can increase the health of beneficiaries while providing savings for 
payers.  
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HIP AND KNEE ARTHROPLASTY: HOW MUCH THESE PROCEDURES IMPACTS IN 
THE BRAZILIAN HEALTH CARE EXPENDITURES?  
Araújo GTB1, Abicalaffe CL2, Savian J2, Decimoni TC1, Santos AM1, Fonseca M3 
1Axia.Bio Consulting, São Paulo, Brazil, 22iM S/A, Curitiba, Brazil, 3Federal University of São 
Paulo / Axia.Bio Consulting, São Paulo, Brazil  
OBJECTIVES: The number of hip and knee arthroplasty has been growing 
steadily over the last decade because they are effective procedures that improve 
quality of life and functional capacity and decrease pain. They have been proven 
to be cost-effective procedures in different countries. The objective of this study 
is to quantify the number and expenditure with these procedures in Brazil. 
METHODS: We used for the public health care system data from the hospital 
information system (SIH/SUS) database and for the private health care data from 
the BI2iM database that has 5 million lives. We used the codes for each of these 
two procedures as search base. All values are in 2010 Brazilian reais (US$1.00=R$ 
2.00). RESULTS: A total of 20,116 hip and 6,320 knee arthroplasties were 
performed in the public system and 20,212 hip and 16,206 knee arthroplasties 
were performed in the private health system. The total expenditure to the 
Brazilian health system generated by these procedures was R$ 584,6 millions. For 
hip procedures the expenses for the public and private systems were 
respectively R$ 60,8 millions and R$ 280 millions. For knee procedures the 
expenses for the public and private systems were R$ 15,3 millions and R$ 228, 5 
